If you're looking to bolster your portfolio with some blue chip shares in March, you may want to look at the two listed below.
Here's why these blue chip ASX shares are highly rated right now:
CSL Limited (ASX: CSL)
The first blue chip share to look at is CSL. This biotherapeutics giant could be a top option for investors looking for exposure to the healthcare sector.
This is thanks to the long term growth potential of its CSL Behring and Seqirus businesses, as well as the soon to be acquired Vifor Pharma business.
The team at Morgans believe now could be the time to buy. Particularly given the improving outlook for plasma collections. It said: "While near term challenges remain, the ongoing recovery in plasma collections, coupled with management's confidence, paints a favourable earnings picture."
Morgans currently has an add rating and $327.60 price target on its shares. This compares favourably to the latest CSL share price of $250.22.
Goodman Group (ASX: GMG)
Another blue chip ASX 200 share to look at is Goodman Group. It is a leading integrated commercial and industrial property company.
Over the last decade, Goodman has built a portfolio of in-demand properties that have exposure to key growth markets such as ecommerce and logistics. And with a material development pipeline and strong demand, Goodman has been tipped to continue its solid growth in the coming years by the team at Citi.
In fact, the broker believes that management's upgraded earnings per share guidance of 20% in FY 2022 is conservative and sees scope for Goodman to outperform it.
Citi has a buy rating and $29.50 price target on the company's shares. This compares to the latest Goodman share price of $21.38.
